研究者業績

臼杵 豊展

ウスキ トヨノブ  (Usuki Toyonobu)

基本情報

所属
上智大学 理工学部物質生命理工学科 教授
学位
学士(理学)(東北大学)
修士(理学)(東北大学)
博士(理学)(東北大学)

連絡先
t-usukisophia.ac.jp
研究者番号
50514535
J-GLOBAL ID
200901076489387829
researchmap会員ID
5000046104

学歴

 3

受賞

 12

論文

 112
  • Christian Nanga Chick, Francois Eya'ane Meva, Phillippe Belle Ebanda Kedi, Toyonobu Usuki
    2024年7月17日  査読有り責任著者
  • Eri Tanaka, Yukie Yokota, Masamitsu Urakawa, Toyonobu Usuki
    European Food Research and Technology 2024年4月21日  査読有り責任著者
  • Lokadi Pierre Luhata, Yusuke Yoshida, Toyonobu Usuki
    Bioorganic Chemistry 147 107389-107389 2024年4月  査読有り責任著者
  • Organic & Biomolecular Chemistry 22(23) 4637-4640 2024年4月  査読有り責任著者
  • Hiroaki Tanaka, Seiya Miyagi, Tomoko Morita, Hiroaki Ishii, Natsuki Mori, Kaho Oishi, Takemasa Sakaguchi, Toyonobu Usuki
    Helvetica Chimica Acta 107(2) 2024年2月8日  査読有り責任著者
    Abstract Umifenovir is a broad‐spectrum antiviral agent used to treat influenza in China and Russia, and it has been studied as an antiviral agent for the treatment of coronavirus disease 2019 (COVID‐19). We have previously reported the synthesis of novel umifenovir analogues and their biological evaluation with a focus on their inhibitory activity against the binding of the spike glycoprotein (S‐protein) of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) and the angiotensin‐converting enzyme 2 (ACE2) receptor; however, no strong inhibitory activity was observed from these analogues. In the present study, an additional set of umifenovir analogues was synthesized with replacement of the substituents at the 2‐, 3‐, and 4‐positions of the indole, and a cell‐based assay using SARS‐CoV‐2 (B.1.1) was performed to examine the antiviral activity of the analogues. We found that one of the newly synthesized umifenovir analogues exhibited antiviral activity and reduced the viral load to 0.06 % as compared to the control when it was assessed in the presence of nafamostat and marimastat, which inhibit cell‐surface viral entry. In contrast, when this analogue was evaluated without the addition of nafamostat or marimastat, it exhibited less antiviral activity, suggesting that the umifenovir analogue would exert antiviral activity mainly by inhibiting endosome‐mediated viral entry.

MISC

 2

書籍等出版物

 2

講演・口頭発表等

 281

共同研究・競争的資金等の研究課題

 22

その他

 7